Results 241 to 250 of about 38,609 (257)

Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis

Med, 2023
Falk Steffen, Frauke Zipp, Stefan Bittner   +2 more
exaly  

Extended dosing of monoclonal antibodies in multiple sclerosis

Multiple Sclerosis Journal, 2022
Alyssa A Toorop, Finn Sellebjerg, Gavin Giovannoni   +2 more
exaly  

Efficacy of Omalizumab Using Extended Dose Intervals

Journal of Allergy and Clinical Immunology, 2007
R.M. Katz, A.W. Rafi, L. Do, M. Lin, R. Mangat, N. Azad, S. Sender   +6 more
openaire   +1 more source

Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic

Journal of the Neurological Sciences, 2021
Gerd Haga Bringeland, Nello Blaser, Kjell-Morten Myhr   +2 more
exaly  

Extended Interval Gentamicin Dosing in Burn Patients

Journal of Burn Care & Rehabilitation, 2001
K. L. Brown, P. R. Mayo, H. A. Shankowsky, E. E. Tredget   +3 more
openaire   +1 more source

Effectiveness of Natalizumab in Extended Dosing Interval (P3.078)

Neurology, 2016
Jose Vicente Hervas, Joan Punet-Ortiz, Aina Teniente-Serra, M Jos Mansilla, Bibiana Quirant-Sanchez, Juan Navarro, Silvia Presas, Eva Martinez-Caceres, Cristina Ramo   +8 more
openaire   +1 more source

Progressive Multifocal Leukoencephalopathy Associated to Natalizumab Extended Dosing Regimen

Neurodegenerative Disease Management, 2015
JOSÉ Vicente Hervas, Silvia Presas-Rodriguez, Cristina Ramo-Tello   +2 more
exaly  

Potential Nephrotoxicity of Both Conventional Interval Dosing and Extended Interval Dosing of Gentamycin in Preterm Infants

Mansoura Journal of Forensic Medicine and Clinical Toxicology, 2005
Essam Ali, Basma Shouman
openaire   +1 more source

Application of Bayes Theorem to Aminoglycoside-Associated Nephrotoxicity: Comparison of Extended-Interval Dosing, Individualized Pharmacokinetic Monitoring, and Multiple-Daily Dosing

Journal of Clinical Pharmacology, 2004
Myong-Jin Kim, Joseph S Bertino, Paul L Jenkins   +2 more
exaly  

Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world

Expert Opinion on Drug Safety, 2023
exaly